8-K Announcements
6Material company update
Apr 8, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Jan 28, 2026·SEC
Nurix Therapeutics, Inc.(NRIX)Earnings, Financials & Key Ratios
NRIX•NASDAQ
$16.88
$1.72B mkt cap·Price updated May 6, 2026
AboutNurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.Show more
- Revenue$84M+54.0%
- EBITDA-$267M-30.1%
- Net Income-$264M-36.6%
- EPS (Diluted)-3.05-5.9%
- Gross Margin77.55%+125.3%
- EBITDA Margin-317.71%+15.5%
- Operating Margin-340.16%+12.9%
- Net Margin-314.9%+11.3%
- ROE-49.63%+6.7%
- ROIC-54.05%-5.2%
- Debt/Equity0.10+92.6%
NRIX Key Insights
Nurix Therapeutics, Inc. (NRIX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 36.3%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 29.1% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NRIX Price & Volume
Nurix Therapeutics, Inc. (NRIX) stock price & volume — 10-year historical chart
Loading chart...
NRIX Growth Metrics
Nurix Therapeutics, Inc. (NRIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years36.35%
3 Years29.55%
TTM53.95%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-36.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-5.19%
Return on Capital
10 Years-56.35%
5 Years-45.84%
3 Years-49.89%
Last Year-48.62%
NRIX Recent Earnings
Nurix Therapeutics, Inc. (NRIX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Apr 8, 2026EPS
$0.79
Est $0.76
-3.9%
Revenue
$6M
Est $14M
-56.1%
Q1 2026
Jan 28, 2026EPS
$0.82
Est $0.84
+2.4%
Revenue
$14M
Est $13M
+1.3%
Q4 2025
Oct 9, 2025EPS
$1.03
Est $0.84
-22.6%
Revenue
$8M
Est $12M
-35.6%
Q3 2025
Jul 9, 2025EPS
$0.52
Est $0.71
+26.8%
Revenue
$44M
Est $18M
+151.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 8, 2026 | $0.79vs $0.76-3.9% | $6Mvs $14M-56.1% |
| Q1 2026 | Jan 28, 2026 | $0.82vs $0.84+2.4% | $14Mvs $13M+1.3% |
| Q4 2025 | Oct 9, 2025 | $1.03vs $0.84-22.6% | $8Mvs $12M-35.6% |
| Q3 2025 | Jul 9, 2025 | $0.52vs $0.71+26.8% | $44Mvs $18M+151.6% |
Based on last 12 quarters of dataView full earnings history →
NRIX Peer Comparison
Nurix Therapeutics, Inc. (NRIX) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 |
Compare NRIX vs Peers
Nurix Therapeutics, Inc. (NRIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NRIX Income Statement
Nurix Therapeutics, Inc. (NRIX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Nov'18 | Nov'19 | Nov'20 | Nov'21 | Nov'22 | Nov'23 | Nov'24 | Nov'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 37.45M | 31.11M | 17.82M | 29.75M | 38.63M | 76.99M | 54.55M | 83.98M |
| Revenue Growth % | - | -16.91% | -42.73% | 66.95% | 29.84% | 99.31% | -29.15% | 53.95% |
| Cost of Goods Sold | 40.51M | 45.02M | 66.49M | 116.43M | 184.5M | 189.15M | 221.63M | 18.86M |
| COGS % of Revenue | 108.18% | 144.71% | 373.14% | 391.37% | 477.64% | 245.69% | 406.3% | 22.45% |
| Gross Profit | -3.06M▲ 0% | -13.91M▼ 353.8% | -48.67M▼ 249.9% | -86.68M▼ 78.1% | -145.87M▼ 68.3% | -112.16M▲ 23.1% | -167.08M▼ 49.0% | 65.12M▲ 139.0% |
| Gross Margin % | -8.18% | -44.71% | -273.14% | -291.37% | -377.64% | -145.69% | -306.3% | 77.55% |
| Gross Profit Growth % | - | -353.83% | -249.92% | -78.09% | -68.28% | 23.11% | -48.97% | 138.98% |
| Operating Expenses | 6.67M | 8.33M | 16.31M | 31.2M | 38M | 42.9M | 45.94M | 350.79M |
| OpEx % of Revenue | 17.82% | 26.76% | 91.52% | 104.88% | 98.37% | 55.73% | 84.23% | 417.71% |
| Selling, General & Admin | 6.67M | 8.33M | 16.31M | 31.2M | 38M | 42.9M | 45.94M | 52.74M |
| SG&A % of Revenue | 17.82% | 26.76% | 91.52% | 104.88% | 98.37% | 55.73% | 84.23% | 62.8% |
| Research & Development | 40.51M | 45.02M | 66.49M | 116.43M | 184.5M | 189.15M | 221.63M | 308.16M |
| R&D % of Revenue | 108.18% | 144.71% | 373.14% | 391.37% | 477.64% | 245.69% | 406.3% | 366.95% |
| Other Operating Expenses | -40.51M | -45.02M | -66.49M | -116.43M | -184.5M | -189.15M | -221.63M | -10.12M |
| Operating Income | -9.74M▲ 0% | -22.24M▼ 128.3% | -64.98M▼ 192.2% | -117.89M▼ 81.4% | -183.87M▼ 56.0% | -155.06M▲ 15.7% | -213.03M▼ 37.4% | -285.67M▼ 34.1% |
| Operating Margin % | -26.01% | -71.46% | -364.66% | -396.26% | -476.01% | -201.41% | -390.52% | -340.16% |
| Operating Income Growth % | - | -128.32% | -192.24% | -81.41% | -55.97% | 15.67% | -37.38% | -34.1% |
| EBITDA | -6.75M | -19.88M | -62.8M | -115.9M | -179.72M | -148.93M | -205.01M | -266.81M |
| EBITDA Margin % | -18.03% | -63.9% | -352.43% | -389.57% | -465.27% | -193.45% | -375.83% | -317.71% |
| EBITDA Growth % | - | -194.5% | -215.88% | -84.54% | -55.07% | 17.13% | -37.65% | -30.15% |
| D&A (Non-Cash Add-back) | 2.99M | 2.35M | 2.18M | 1.99M | 4.15M | 6.13M | 8.02M | 18.86M |
| EBIT | -9.74M | -22.24M | -64.98M | -117.89M | -183.87M | -155.06M | -213.03M | -263.7M |
| Net Interest Income | 818K | 776K | 1.21M | 823K | 3.51M | 11.12M | 19.73M | 21.97M |
| Interest Income | 818K | 776K | 1.21M | 823K | 3.51M | 11.12M | 19.73M | 21.97M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 818K | 776K | 1.21M | 823K | 3.51M | 11.12M | 19.73M | 21.97M |
| Pretax Income | -8.92M▲ 0% | -21.46M▼ 140.6% | -63.78M▼ 197.2% | -117.06M▼ 83.6% | -180.36M▼ 54.1% | -143.95M▲ 20.2% | -193.3M▼ 34.3% | -263.7M▼ 36.4% |
| Pretax Margin % | -23.82% | -68.97% | -357.9% | -393.49% | -466.93% | -186.98% | -354.36% | -314% |
| Income Tax | 507K | 239K | -20.54M | 131K | 0 | 0 | 270K | 760K |
| Effective Tax Rate % | -5.68% | -1.11% | 32.2% | -0.11% | 0% | 0% | -0.14% | -0.29% |
| Net Income | -9.43M▲ 0% | -21.7M▼ 130.2% | -43.24M▼ 99.3% | -117.19M▼ 171.0% | -180.36M▼ 53.9% | -143.95M▲ 20.2% | -193.57M▼ 34.5% | -264.46M▼ 36.6% |
| Net Margin % | -25.18% | -69.74% | -242.66% | -393.93% | -466.93% | -186.98% | -354.85% | -314.9% |
| Net Income Growth % | - | -130.15% | -99.28% | -171.02% | -53.9% | 20.19% | -34.47% | -36.62% |
| Net Income (Continuing) | -9.43M | -21.7M | -43.24M | -117.19M | -180.36M | -143.95M | -193.57M | -264.46M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.59▲ 0% | -0.56▲ 5.1% | -2.76▼ 392.9% | -2.73▲ 1.1% | -3.71▼ 35.9% | -2.65▲ 28.6% | -2.88▼ 8.7% | -3.05▼ 5.9% |
| EPS Growth % | - | 5.08% | -392.86% | 1.09% | -35.9% | 28.57% | -8.68% | -5.9% |
| EPS (Basic) | -0.59 | -0.56 | -2.76 | -2.73 | -3.71 | -2.65 | -2.88 | -3.05 |
| Diluted Shares Outstanding | 16.11M | 38.85M | 15.67M | 42.9M | 48.61M | 54.34M | 67.12M | 86.67M |
| Basic Shares Outstanding | 16.11M | 38.85M | 15.67M | 42.9M | 48.61M | 54.34M | 67.12M | 86.67M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
NRIX Balance Sheet
Nurix Therapeutics, Inc. (NRIX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Nov'18 | Nov'19 | Nov'20 | Nov'21 | Nov'22 | Nov'23 | Nov'24 | Nov'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 40.65M | 39.35M | 298.43M | 311.12M | 318.45M | 295.5M | 619.39M | 606.82M |
| Cash & Short-Term Investments | 39.04M | 37.72M | 281.15M | 295.72M | 309.14M | 287.91M | 609.58M | 592.94M |
| Cash Only | 25.59M | 34.82M | 119.36M | 80.51M | 64.47M | 54.63M | 110M | 246.96M |
| Short-Term Investments | 13.45M | 2.9M | 161.79M | 215.21M | 244.67M | 233.28M | 499.59M | 345.98M |
| Accounts Receivable | 0 | 0 | 11.35M | 6.2M | 1.1M | 800K | 1.5M | 0 |
| Days Sales Outstanding | - | - | 232.4 | 76.12 | 10.39 | 3.79 | 10.04 | - |
| Inventory | 0 | 0 | 0 | 0 | -1.1M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 900K | 9.31M | 6.79M | 8.3M | 13.88M |
| Total Non-Current Assets | 4.74M | 4.69M | 97.91M | 165.65M | 98.31M | 60.09M | 49.96M | 81.32M |
| Property, Plant & Equipment | 4.42M | 3.87M | 6.67M | 25.34M | 29.51M | 47.95M | 45.9M | 73.01M |
| Fixed Asset Turnover | 8.47x | 8.04x | 2.67x | 1.17x | 1.31x | 1.61x | 1.19x | 1.15x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 170K | 506K | 90.89M | 137.47M | 63.88M | 7.42M | 0 | 0 |
| Other Non-Current Assets | 151K | 317K | 347K | 3.12M | 4.92M | 4.72M | 4.06M | 8.31M |
| Total Assets | 45.4M▲ 0% | 44.05M▼ 3.0% | 396.34M▲ 799.8% | 476.77M▲ 20.3% | 416.76M▼ 12.6% | 355.6M▼ 14.7% | 669.34M▲ 88.2% | 688.13M▲ 2.8% |
| Asset Turnover | 0.82x | 0.71x | 0.04x | 0.06x | 0.09x | 0.22x | 0.08x | 0.12x |
| Asset Growth % | - | -2.97% | 799.8% | 20.29% | -12.59% | -14.68% | 88.23% | 2.81% |
| Total Current Liabilities | 32.83M | 16.14M | 44.54M | 66.26M | 70.66M | 86.96M | 95.85M | 86.47M |
| Accounts Payable | 1.3M | 1.6M | 3.41M | 6.65M | 5.06M | 6.4M | 11.48M | 11.21M |
| Days Payables Outstanding | 11.69 | 12.95 | 18.73 | 20.85 | 10.02 | 12.35 | 18.91 | 217.09 |
| Short-Term Debt | 0 | 0 | 0 | 3.85M | 5.53M | 7.49M | 0 | 0 |
| Deferred Revenue (Current) | 28.42M | 9.61M | 32.8M | 41.21M | 37.63M | 48.1M | 38.36M | 17.58M |
| Other Current Liabilities | 726K | 1.18M | 2.6M | 5.67M | 9.14M | 751K | 18.91M | 23.64M |
| Current Ratio | 1.24x | 2.44x | 6.70x | 4.70x | 4.51x | 3.40x | 6.46x | 7.02x |
| Quick Ratio | 1.24x | 2.44x | 6.70x | 4.70x | 4.52x | 3.40x | 6.46x | 7.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 49.41M | 85.63M | 61.53M | 68.21M | 42.41M | 68.15M | 46.5M | 62.92M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 9.19M | 6.43M | 23.13M | 20.29M | 52.91M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.22M | 1.74M | 850K | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 34.05M | 53.57M | 106.07M | 134.47M | 113.06M | 155.1M | 142.35M | 149.39M |
| Total Debt | 0 | 0 | 0 | 13.04M | 11.96M | 30.61M | 28.3M | 55.73M |
| Net Debt | -25.59M | -34.82M | -119.36M | -67.47M | -52.51M | -24.01M | -81.69M | -191.23M |
| Debt / Equity | - | - | - | 0.04x | 0.04x | 0.15x | 0.05x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | -36.85M▲ 0% | -57.71M▼ 56.6% | 290.27M▲ 602.9% | 342.3M▲ 17.9% | 303.7M▼ 11.3% | 200.49M▼ 34.0% | 526.99M▲ 162.8% | 538.75M▲ 2.2% |
| Equity Growth % | - | -56.63% | 602.94% | 17.93% | -11.28% | -33.98% | 162.85% | 2.23% |
| Book Value per Share | -2.29 | -1.49 | 18.52 | 7.98 | 6.25 | 3.69 | 7.85 | 6.22 |
| Total Shareholders' Equity | -36.85M | -57.71M | 290.27M | 342.3M | 303.7M | 200.49M | 526.99M | 538.75M |
| Common Stock | 3K | 4K | 39K | 45K | 47K | 49K | 76K | 102K |
| Retained Earnings | -38.76M | -60.46M | -103.7M | -220.89M | -401.25M | -545.2M | -738.77M | -1B |
| Treasury Stock | -1.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4K | -2K | 87K | -608K | -4.32M | -655K | 150K | 105K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRIX Cash Flow Statement
Nurix Therapeutics, Inc. (NRIX) cash flow — operating, investing & free cash flow history
| Line item | Nov'18 | Nov'19 | Nov'20 | Nov'21 | Nov'22 | Nov'23 | Nov'24 | Nov'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -31.68M | 601K | -80K | -84.36M | -159.81M | -81.36M | -172.58M | -249.47M |
| Operating CF Margin % | -84.58% | 1.93% | -0.45% | -283.58% | -413.72% | -105.69% | -316.38% | -297.05% |
| Operating CF Growth % | - | 101.9% | -113.31% | -105356.25% | -89.42% | 49.09% | -112.11% | -44.55% |
| Net Income | -9.43M | -21.7M | -43.24M | -117.19M | -180.36M | -143.95M | -193.57M | -264.46M |
| Depreciation & Amortization | 2.99M | 2.35M | 2.18M | 6.08M | 10.81M | 13.65M | 16.43M | 18.86M |
| Stock-Based Compensation | 431K | 510K | 4.3M | 15.8M | 28.13M | 33.67M | 33.93M | 37.97M |
| Deferred Taxes | -354K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -6K | -109K | 273K | 1.83M | 636K | -4.87M | -10.97M | -10.23M |
| Working Capital Changes | -25.31M | 19.55M | 36.41M | 9.11M | -19.02M | 20.12M | -18.4M | -31.6M |
| Change in Receivables | 12.37M | 0 | -11.35M | -6M | 6M | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 6.77M | 0 | 0 | 0 | 0 |
| Change in Payables | -519K | 302K | 1.23M | 1.59M | 85K | 1.61M | 5.21M | -630K |
| Cash from Investing | 39.99M | 8.5M | -254.4M | -108.25M | 27.2M | 68.3M | -257.71M | 147.85M |
| Capital Expenditures | -1.59M | -1.65M | -4.55M | -5.66M | -12.24M | -8.4M | -9.27M | -14M |
| CapEx % of Revenue | 4.26% | 5.31% | 25.55% | 19.03% | 31.7% | 10.91% | 17% | 16.67% |
| Acquisitions | 6K | -10.15M | 249.85M | 102.59M | -39.44M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 10.15M | -249.85M | -102.59M | 39.44M | 0 | 0 | 0 |
| Cash from Financing | 529K | 126K | 339.02M | 153.88M | 117.19M | 3.22M | 485.67M | 238.64M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 529K | 126K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -2K | -16K | -7K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 963K | 3.73M | 97.79M | 0 | 7.17M | 0 |
| Net Change in Cash | 8.85M▲ 0% | 9.22M▲ 4.3% | 84.54M▲ 816.4% | -38.73M▼ 145.8% | -15.42M▲ 60.2% | -9.85M▲ 36.1% | 55.37M▲ 662.3% | 137.03M▲ 147.5% |
| Free Cash Flow | -33.27M▲ 0% | -1.05M▲ 96.8% | -4.63M▼ 341.2% | -90.03M▼ 1843.1% | -172.05M▼ 91.1% | -89.77M▲ 47.8% | -181.86M▼ 102.6% | -263.47M▼ 44.9% |
| FCF Margin % | -88.84% | -3.37% | -26% | -302.61% | -445.42% | -116.6% | -333.38% | -313.73% |
| FCF Growth % | - | 96.84% | -341.24% | -1843.15% | -91.11% | 47.83% | -102.59% | -44.88% |
| FCF per Share | -2.07 | -0.03 | -0.30 | -2.10 | -3.54 | -1.65 | -2.71 | -3.04 |
| FCF Conversion (FCF/Net Income) | 3.36x | -0.03x | 0.00x | 0.72x | 0.89x | 0.57x | 0.89x | 0.94x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 1K | 1K | 1K | 481K | 0 | 0 | 0 | 0 |
NRIX Key Ratios
Nurix Therapeutics, Inc. (NRIX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -37.19% | -37.05% | -55.84% | -57.1% | -53.22% | -49.63% |
| Return on Invested Capital (ROIC) | - | - | -124.36% | -39.67% | -52.43% | -54.39% | -51.39% | -54.05% |
| Gross Margin | -8.18% | -44.71% | -273.14% | -291.37% | -377.64% | -145.69% | -306.3% | 77.55% |
| Net Margin | -25.18% | -69.74% | -242.66% | -393.93% | -466.93% | -186.98% | -354.85% | -314.9% |
| Debt / Equity | - | - | - | 0.04x | 0.04x | 0.15x | 0.05x | 0.10x |
| FCF Conversion | 3.36x | -0.03x | 0.00x | 0.72x | 0.89x | 0.57x | 0.89x | 0.94x |
| Revenue Growth | - | -16.91% | -42.73% | 66.95% | 29.84% | 99.31% | -29.15% | 53.95% |
NRIX SEC Filings & Documents
Nurix Therapeutics, Inc. (NRIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
NRIX Frequently Asked Questions
Nurix Therapeutics, Inc. (NRIX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nurix Therapeutics, Inc. (NRIX) reported $84.0M in revenue for fiscal year 2025. This represents a 124% increase from $37.4M in 2018.
Nurix Therapeutics, Inc. (NRIX) grew revenue by 54.0% over the past year. This is strong growth.
Nurix Therapeutics, Inc. (NRIX) reported a net loss of $264.5M for fiscal year 2025.
Dividend & Returns
Nurix Therapeutics, Inc. (NRIX) has a return on equity (ROE) of -49.6%. Negative ROE indicates the company is unprofitable.
Nurix Therapeutics, Inc. (NRIX) had negative free cash flow of $263.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More NRIX
Nurix Therapeutics, Inc. (NRIX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates